Roche has become a global leader in many fields:
Ranked first in the field of global diagnosis.
Ranked first in the global cancer field.
A leader in transplantation and virology
Ranked second in the global biotechnology field.
Traditionally, 65,438+05% of Roche's total annual sales revenue is invested in the field of scientific research and development, which is the highest among its peers. This tradition of attaching importance to scientific research has not only enabled Roche to develop a variety of breakthrough new drugs, but also achieved considerable economic benefits. In addition, the social benefits of promoting human health are also extremely outstanding, and Roche scientists won the Nobel Prize for this three times. At present, Roche has 65,438+00 R&D centers in the world, located in Basel, Switzerland, Natley, USA and Palo Alto. Among them, Roche's Central Nervous System and Cardiovascular Disease Research Center in Basel and American Gene Research Center enjoy a high reputation in the international medical community. On June 5438+ 10, 2004, Roche announced the establishment of the fifth pharmaceutical R&D center in Shanghai, China. This will be the first time Roche has established an R&D factory in a developing country.
Roche pharmaceutical production department has a long history, mainly producing drugs for treating central nervous system diseases, infectious diseases, inflammation, cardiovascular diseases, tumors, viral infections, skin diseases, obesity and other diseases. In order to increase the variety and innovation of drugs, Roche has successfully acquired some large international pharmaceutical companies in recent years to strengthen its own strength. These include: acquiring a majority stake in Genentech, the most advanced bioengineering company in the United States, and strengthening Roche's leading position in genetic engineering in the forefront of the pharmaceutical industry; Acquired the over-the-counter department of Nicholas Company and Fei Sen Company, making Roche the largest company in the over-the-counter market in Europe; 1994, the company acquired Cintex Pharmaceutical Company, which doubled Roche's strength in anti-infection and organ transplant drugs. In 20001year, Roche and Japanese and foreign pharmaceutical companies announced the joint establishment of a leading research-oriented Japanese pharmaceutical company, which is a fully functional multinational company headquartered in Japan and ranks fifth in the Japanese market, the second largest pharmaceutical sales market in the world.
Since the establishment of 1968, Roche Medical Diagnosis Department has developed at an amazing speed. The reagents produced by this department are widely used in medical immunological tests, such as pregnancy test, hepatitis test and HIV test. From 65438 to 0994, Roche Biomedical Laboratory merged with the National Health Laboratory of the United States to form the largest clinical laboratory organization in the world-American Laboratory Organization, in which Roche owns 49.9% of the shares. In medical diagnosis, Roche Molecular Laboratory is another research institution with outstanding achievements in Roche. At present, the laboratory is committed to the research of polymerase chain reaction (PCR), which can replicate the same gene or DNA fragment repeatedly and can be widely used in basic research, diagnosis of AIDS, tuberculosis and leukemia and environmental detection. At the beginning of 1998, Roche completely completed the acquisition of Bolinman Company, absorbed the advantages of this company in products, and became a pioneer in the field of medical diagnosis. In 2003, Roche successfully acquired the Swiss Disetronic Company, the second largest insulin pump manufacturer in the world, making Roche Diagnostics Department, which has the world-leading technology in the field of diabetes monitoring, the most important supplier of comprehensive diabetes control system equipment in the world.
1896
Hofmeroch Company was established.
19 19
Roche changed from a family company to a limited company.
1933
Industrial synthesis of vitamin c
1938- 1947
Industrial Synthesis of Vitamin A, Vitamin B and Vitamin E
1963
Acquisition of Chivaton Flavors and Fragrances Company
1964
Acquisition of Loya company
1968
Establish a diagnostic product department
1968
Roche Institute of Molecular Biology was established in Natley, USA.
197 1
Roche Institute of Immunology was established in Basel.
1974
The anti-Parkinson drug Madopar won the Galen Prize.
1975
The first large-scale production of monoclonal antibodies.
1980
Started working with Genentech in the United States.
1984
Tigason, the first drug that can effectively treat severe psoriasis, won the Galen Prize.
1984
Professor Nelskaya Jayne and Dr George Le, who work in Roche Basel Institute of Immunology, won the Nobel Prize in Physiology and Medicine.
1986
A vision and life research group has been set up to provide assistance for the prevention and treatment of vitamin A deficiency for infants and children in developing countries.
1987
Susumu Tonegowa, a scientist, won the Nobel Prize in Medicine for his outstanding contribution to the Basel Institute of Immunology.
1988
Anexate, an antagonist of benzodiazepines, won the Galen Prize.
1989
Set up Roche Holdings Limited
1990
Acquisition of OTC manufacturer Nicholas Group
199 1
Chivas Roya was established, and Roche Flavors and Fragrances Department was established.
199 1
Neupogen won the European Galen Prize.
1994
Acquisition of Syntek company in the United States
1995
Pulmozyme won the Galen Prize.
1997
Acquired American perfume manufacturer Tesimei Company, and then merged into the fragrance department.
1997
Acquisition of Bowringman and Depp
1997
Won the Galen Prize for Invirase.
1998
The biotechnology research and production center in Penzberg, Germany was completed.
1999
Started to cooperate with deCode company in Iceland.
1999
Full acquisition of Genentech
2000
Roche divested flavor and fragrance business
200 1
Roche Corporation of Japan and Chinese and foreign pharmaceutical companies announced the merger and jointly established a new leader in Japanese pharmaceutical industry.
2002
Roche announced the spin-off of the vitamins and fine chemicals division, which enabled the group to focus more on the health care business.
2003
Roche acquired the Swiss company Disetornic to further strengthen its advantages in the field of diabetes treatment.